5 Feb 2025director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Executive Officer Thomas J. Schaefer bought 700 shares on the open market at $2.49.
Announcements, explained
Each one in plain English, with the numbers worked through for a shareholder.
5 Feb 2025director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Financial Officer Mark Kawakami bought 700 shares on the open market at $2.49.
3 Jan 2025substantial holder notice● Neutral
SABBY MANAGEMENT, LLC reported a Arcadia Biosciences, Inc. shareholding of 4.90% of votes in a periodic institutional filing.
11 Dec 2024business combination▲ GoodMajor
Arcadia announced an all-stock business combination with Roosevelt Resources, LP, a Texas oil-and-gas exploration and production limited partnership formed in 2011 -- structured as a reverse merger in which Roosevelt's limited partners would end up owning approximately 90% of the combined company and existing Arcadia stockholders just 10%, effectively taking Roosevelt public through Arcadia's Nasdaq shell rather than a conventional biotech/ag transaction.
12 Nov 2024quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $1.5 million and a net loss of $1.6 million for the period ended 2024-09-30.
12 Nov 2024quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $1.5 million and a net loss of $1.6 million for the period ended 2024-09-30.
21 Aug 2024director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Executive Officer Thomas J. Schaefer received a stock option grant for 20,000 shares.
21 Aug 2024director interest notice● Neutral
Arcadia Biosciences, Inc. insider Deborah D Carosella received a stock option grant for 10,909 shares.
21 Aug 2024director interest notice● Neutral
Arcadia Biosciences, Inc. insider Albert D. Bolles received a stock option grant for 10,909 shares.
21 Aug 2024director interest notice● Neutral
Arcadia Biosciences, Inc. insider Lilian Shackelford Murray received a stock option grant for 10,909 shares.
21 Aug 2024director interest notice● Neutral
Arcadia Biosciences, Inc. insider Gregory D Waller received a stock option grant for 10,909 shares.
21 Aug 2024director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Financial Officer Mark Kawakami received a stock option grant for 20,000 shares.
21 Aug 2024director interest notice● Neutral
Arcadia Biosciences, Inc. insider Kevin Comcowich received a stock option grant for 25,455 shares.
21 Aug 2024director interest notice● Neutral
Arcadia Biosciences, Inc. insider Amy Yoder received a stock option grant for 10,909 shares.
20 Aug 2024director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Financial Officer Mark Kawakami bought 700 shares on the open market at $2.06.
20 Aug 2024director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Executive Officer Thomas J. Schaefer bought 700 shares on the open market at $2.06.
13 Aug 2024quarterly activities report● Neutral
Arcadia Biosciences, Inc. reported quarterly revenue of $1.3 million and net income of $1.1 million for the period ended 2024-06-30.
13 Aug 2024quarterly activities report● Neutral
Arcadia Biosciences, Inc. reported quarterly revenue of $1.3 million and net income of $1.1 million for the period ended 2024-06-30.
18 July 2024director interest notice● Neutral
Mark Kawakami became a Arcadia Biosciences, Inc. Chief Financial Officer and company insider (initial ownership filing).
20 May 2024asset acquisition disposition▼ BadMajor
Arcadia sold its GoodWheat business to Above Food and transferred $2 million in cash at closing, in exchange for a $6 million promissory note, so net consideration was $4 million. The note pays $2 million of principal plus interest on each of the first three anniversaries and is secured by the purchased assets other than inventory.
17 May 2024asset acquisition disposition▲ GoodMajor
Arcadia sold and licensed its resistant starch durum wheat trait IP to Pioneer Hi-Bred International (a Corteva subsidiary that had worked on the trait since 2017) for $4 million cash -- monetizing a legacy licensing relationship.
13 May 2024quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $987 thousand and a net loss of $2.4 million for the period ended 2024-03-31.
9 May 2024quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $987 thousand and a net loss of $2.4 million for the period ended 2024-03-31.
14 Feb 2024substantial holder notice● Neutral
Armistice Capital, LLC, Steven Boyd reported a Arcadia Biosciences, Inc. shareholding of 58,315 shares (4.99% of votes) in a periodic institutional filing.
5 Feb 2024director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Financial Officer Thomas J. Schaefer bought 700 shares on the open market at $2.06.
9 Nov 2023quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $1.3 million and a net loss of $2.6 million for the period ended 2023-09-30.
9 Nov 2023quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $1.3 million and a net loss of $2.6 million for the period ended 2023-09-30.
10 Aug 2023quarterly activities report● Neutral
Arcadia Biosciences, Inc. reported quarterly revenue of $1.3 million and net income of $823 thousand for the period ended 2023-06-30.
10 Aug 2023quarterly activities report● Neutral
Arcadia Biosciences, Inc. reported quarterly revenue of $1.3 million and net income of $823 thousand for the period ended 2023-06-30.
7 Aug 2023director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Financial Officer Thomas J. Schaefer bought 649 shares on the open market at $3.67.